87 related articles for article (PubMed ID: 8564955)
1. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer.
Eisinger F; Stoppa-Lyonnet D; Longy M; Kerangueven F; Noguchi T; Bailly C; Vincent-Salomon A; Jacquemier J; Birnbaum D; Sobol H
Cancer Res; 1996 Feb; 56(3):471-4. PubMed ID: 8564955
[TBL] [Abstract][Full Text] [Related]
2. Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers.
Sobol H; Stoppa-Lyonnet D; Bressac-de-Paillerets B; Peyrat JP; Kerangueven F; Janin N; Noguchi T; Eisinger F; Guinebretiere JM; Jacquemier J; Birnbaum D
Cancer Res; 1996 Jul; 56(14):3216-9. PubMed ID: 8764110
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women.
Noguchi S; Kasugai T; Miki Y; Fukutomi T; Emi M; Nomizu T
Cancer; 1999 May; 85(10):2200-5. PubMed ID: 10326698
[TBL] [Abstract][Full Text] [Related]
4. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history.
Rebbeck TR; Wang Y; Kantoff PW; Krithivas K; Neuhausen SL; Godwin AK; Daly MB; Narod SA; Brunet JS; Vesprini D; Garber JE; Lynch HT; Weber BL; Brown M
Cancer Res; 2001 Jul; 61(14):5420-4. PubMed ID: 11454686
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers.
Phillips KA
J Clin Oncol; 2000 Nov; 18(21 Suppl):107S-12S. PubMed ID: 11060337
[TBL] [Abstract][Full Text] [Related]
7. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Pharoah PD; Easton DF; Stockton DL; Gayther S; Ponder BA
Cancer Res; 1999 Feb; 59(4):868-71. PubMed ID: 10029077
[TBL] [Abstract][Full Text] [Related]
8. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
Vaziri SA; Krumroy LM; Rostai M; Casey G
Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249
[TBL] [Abstract][Full Text] [Related]
9. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
[TBL] [Abstract][Full Text] [Related]
10. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
Ligtenberg MJ; Hogervorst FB; Willems HW; Arts PJ; Brink G; Hageman S; Bosgoed EA; Van der Looij E; Rookus MA; Devilee P; Vos EM; Wigbout G; Struycken PM; Menko FH; Rutgers EJ; Hoefsloot EH; Mariman EC; Brunner HG; Van 't Veer LJ
Br J Cancer; 1999 Mar; 79(9-10):1475-8. PubMed ID: 10188893
[TBL] [Abstract][Full Text] [Related]
12. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
[TBL] [Abstract][Full Text] [Related]
13. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
14. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
[TBL] [Abstract][Full Text] [Related]
15. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
[TBL] [Abstract][Full Text] [Related]
16. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.
Vahteristo P; Eerola H; Tamminen A; Blomqvist C; Nevanlinna H
Br J Cancer; 2001 Mar; 84(5):704-8. PubMed ID: 11237395
[TBL] [Abstract][Full Text] [Related]
17. Mutations at BRCA1: the medullary breast carcinoma revisited.
Eisinger F; Jacquemier J; Charpin C; Stoppa-Lyonnet D; Bressac-de Paillerets B; Peyrat JP; Longy M; Guinebretière JM; Sauvan R; Noguchi T; Birnbaum D; Sobol H
Cancer Res; 1998 Apr; 58(8):1588-92. PubMed ID: 9563465
[TBL] [Abstract][Full Text] [Related]
18. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.
Lakhani SR; Gusterson BA; Jacquemier J; Sloane JP; Anderson TJ; van de Vijver MJ; Venter D; Freeman A; Antoniou A; McGuffog L; Smyth E; Steel CM; Haites N; Scott RJ; Goldgar D; Neuhausen S; Daly PA; Ormiston W; McManus R; Scherneck S; Ponder BA; Futreal PA; Peto J; Stoppa-Lyonnet D; Bignon YJ; Stratton MR
Clin Cancer Res; 2000 Mar; 6(3):782-9. PubMed ID: 10741697
[TBL] [Abstract][Full Text] [Related]
19. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
20. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
